Blog
Latest articles, insights, and updates from the blog.
Why Clinicians Are Pushing Harder on TRD Goals
New clinical thinking on treatment-resistant depression pushes toward true remission, not just symptom reduction. Here's what it means for ketamine patients.
Ketamine Side Effects & When to Switch: New Clinical Guidance
New clinical guidance urges tracking PHQ-9 scores, monitoring side effects closely, and switching NMDA treatments sooner to reach remission faster.
Rethinking Treatment-Resistant Depression Care in 2026
New clinical perspectives on treatment-resistant depression push for true remission over symptom reduction. Here's what it means for ketamine patients.
Psychedelics Executive Order: What It Means for Ketamine
A new executive order targets psychedelic medicine access. Here's what the policy shift means for low-dose ketamine patients and providers in 2026.
NMDA Antagonist Side Effects: What the Data Now Shows
Psychiatric Times reviews side effect profiles and dropout rates for NMDA antagonists like ketamine. Here's what it means for low-dose ketamine patients.
Insurance Gaps in Ketamine Care — And One Fix
Most health insurers deny coverage for ketamine depression treatment in 2026. Here's what that means for patients and how access gaps are being bridged.
How Clinicians Choose TRD Treatments in 2026
New clinical guidance on treatment-resistant depression highlights how patient preference, speed of response, and functional outcomes shape ketamine treatment decisions.
Esketamine's Role in Treatment-Resistant Depression
A new clinical overview examines esketamine's place in TRD care, including patient selection, access barriers, and rapid-acting benefits for suicidal ideation.
Glutamate Pathway Treatments Reshape TRD Care in 2026
A 2026 review in Psychiatric Times highlights how esketamine and glutamate-targeting drugs are changing treatment-resistant depression care.
TRD Management: Why Remission Should Be the Goal
New clinical guidance on treatment-resistant depression urges full remission over symptom reduction — here's what it means for low-dose ketamine patients.
TRD Experts Push for Remission, Not Just Response
Psychiatrists are shifting TRD goals from symptom reduction to full remission. Here's what that means for ketamine patients and their treatment plans.
Beyond 'Less Bad': Rethinking Treatment-Resistant Depression
Clinicians are pushing beyond symptom reduction in treatment-resistant depression, aiming for full remission. Here's what that means for ketamine patients.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.